Dexcom (DXCM) Total Current Liabilities (2010 - 2026)

Dexcom (DXCM) has reported Total Current Liabilities for 17 consecutive years, with $2.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 28.74% year-over-year to $2.4 billion in Q2 2026; TTM through Jun 2026 was $2.4 billion, a 28.74% decrease from a year earlier, with the FY2025 full-year figure at $2.1 billion, down 26.93% from the prior year.
• Total Current Liabilities was $2.4 billion for Q2 2026 at Dexcom, up from $2.2 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $3.3 billion in Q3 2025 and troughed at $711.4 million in Q1 2022.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 162.16% in 2023 and retreated 28.74% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $1.8 billion in 2022, then dropped by 15.4% to $1.6 billion in 2023, then soared by 88.43% to $2.9 billion in 2024, then decreased by 26.93% to $2.1 billion in 2025, then increased by 10.04% to $2.4 billion in 2026.
• The last three Total Current Liabilities figures came in at $2.4 billion (Q2 2026), $2.2 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.